The effect of infliximab on circulating levels of leptin, adiponectin and resistin in patients with inflammatory bowel disease
| Autor: | Konstantinos Karmiris, C. Xidakis, Elias A. Kouroumalis, Ioannis E. Koutroubakis, Maria Polychronaki |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
Leptin Male medicine.medical_specialty Peptide Hormones Adipokine Inflammatory bowel disease Body Mass Index Gastrointestinal Agents Internal medicine medicine Humans Resistin Prospective Studies Crohn's disease Hepatology Adiponectin Tumor Necrosis Factor-alpha business.industry Gastroenterology Antibodies Monoclonal Middle Aged Inflammatory Bowel Diseases medicine.disease Ulcerative colitis Infliximab digestive system diseases C-Reactive Protein Endocrinology Immunology Female business Biomarkers medicine.drug |
| Zdroj: | European Journal of Gastroenterology & Hepatology. 19:789-794 |
| ISSN: | 0954-691X |
| DOI: | 10.1097/meg.0b013e3282202bca |
| Popis: | Tumour necrosis factor alpha is a critical mediator of inflammation-related altered metabolism in inflammatory bowel disease (IBD), possibly through its interaction with adipokines, which play an important role in IBD. Infliximab is a well established antitumour necrosis factor alpha treatment in IBD.We studied serum levels of leptin, adiponectin and resistin in 20 IBD patients before and after infliximab treatment using commercially available enzyme-linked immunosorbent assays. The results were correlated with alterations of disease activity, BMI and C-reactive protein.Infliximab induced clinical response or remission in 18 out of 20 treated IBD patients. Mean serum-leptin levels were 4.6+/-0.5 and 5.1+/-0.5 ng/ml (P=0.41), mean serum-adiponectin levels were 10513.9+/-1216.9 and 9653.5+/-1031.5 ng/ml (P=0.36) and mean serum-resistin levels were 26.3+/-4.1 and 13.9+/-1.4 ng/ml (P=0.004), before and after infliximab treatment, respectively. No significant correlation between the changes of BMI, C-reactive protein or the clinical indices of activity and alterations of the examined adipokines was found.Serum levels of leptin and adiponectin had no significant alterations, whereas serum-resistin levels are significantly decreased after infliximab therapy in IBD patients, suggesting a possible proinflammatory status for resistin in IBD and a role as a marker of successful therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|